KZR — Kezar Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $62.81m
- -$128.50m
- $7.00m
- 18
- 34
- 32
- 18
Annual cashflow statement for Kezar Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -35.1 | -41.7 | -54.6 | -68.2 | -102 |
| Depreciation | |||||
| Non-Cash Items | 3.03 | 5.26 | 9.46 | 12.8 | 14.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.881 | -2.01 | 1.23 | -4.46 | 4.71 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -29.9 | -36.9 | -42.4 | -58.8 | -81.6 |
| Capital Expenditures | -0.607 | -0.194 | -0.316 | -1.58 | -1.81 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 21 | -56.3 | -28.1 | -89.8 | 77.9 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 20.4 | -56.5 | -28.4 | -91.4 | 76 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.272 | 99.6 | 113 | 128 | 0.638 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -9.23 | 6.28 | 41.7 | -22.4 | -4.96 |